NCT07505771

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Early IRecruitingImmunome, Inc.

Solid Malignancies

See how this trial matches your record

Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.

Summary

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Interventions

DRUG177Lu-IM-3050

Eligibility

Inclusion criteria

Must be at least 18 years old

Locations

Texas

University of Texas - MD Anderson Cancer Center
Houston, Texas
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas